Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep;9(9):806-15.
doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19.

Infliximab-Related Infusion Reactions: Systematic Review

Lev Lichtenstein  1 , Yulia Ron  2 , Shmuel Kivity  3 , Shomron Ben-Horin  3 , Eran Israeli  4 , Gerald M Fraser  5 , Iris Dotan  2 , Yehuda Chowers  6 , Ronit Confino-Cohen  7 , Batia Weiss  8
Affiliations
Review

Infliximab-Related Infusion Reactions: Systematic Review

Lev Lichtenstein et al. J Crohns Colitis. 2015 Sep.

Abstract

Objective: Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this study is to perform a systematic review of the evidence behind the strategies for preventing infusion reactions to infliximab, and for controlling the reactions once they occur.

Methods: We conducted extensive search of electronic databases of MEDLINE [PubMed] for reports that communicate various aspects of infusion reactions to infliximab in IBD patients.

Results: We examined full texts of 105 potentially eligible articles. No randomised controlled trials that pre-defined infusion reaction as a primary outcome were found. Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analysis; and 62 additional studies focused on various aspects of mechanism/s, risk, primary and secondary preventive measures, and management algorithms. Seven studies were added by a manual search of reference lists of the relevant articles. A total of 76 original studies were included in quantitative analysis of the existing strategies.

Conclusions: There is still paucity of systematic and controlled data on the risk, prevention, and management of infusion reactions to infliximab. We present working algorithms based on systematic and extensive review of the available data. More randomised controlled trials are needed in order to investigate the efficacy of the proposed preventive and management algorithms.

Keywords: Crohn’s disease; Infliximab; adverse drug reaction; drug allergy; drug hypersensitivity; drug toxicity; inflammatory bowel disease; infusion reactions; ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of the literature search.
Figure 2.
Figure 2.
Suggested management algorithm for infusion reactions.
Figure 3.
Figure 3.
Suggested premedication protocol in patients with prior infusion reactions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adler J, Sandberg KC, Shpeen BH, et al. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013;57:35–8. - PubMed
    1. Keshavarzian A, Mayer L, Salzberg B, et al. A multicenter retrospective experience of infliximab in Crohn’s disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol 2007;3:381–90. - PMC - PubMed
    1. Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798–805. - PubMed
    1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9. - PubMed
    1. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85. - PubMed

MeSH terms